Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
15.57%
↑ 116% vs avg
Percentile
P100
Near historical high
Streak
4 yr
Consecutive growthExpanding
Average
-94.66%
Historical baseline
PeriodValueYoY Change
TTM15.57%+583.6%
20242.28%+101.8%
2023-129.03%+44.8%
2022-233.65%+17.5%
2021-283.18%-435.5%
2020-52.88%+11.6%
2019-59.80%+46.0%
2018-110.76%-24196.8%
2013-0.46%-